The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria
© Draper et al.; licensee BioMed Central Ltd. 2013
Received: 7 August 2013
Accepted: 19 September 2013
Published: 26 September 2013
The emergence of bacterial drug resistance encourages the re-evaluation of the potential of existing antimicrobials. Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial peptides with a broad spectrum antimicrobial activity. Here, we focussed on expanding the potential of lacticin 3147, one of the most studied lantibiotics and one which possesses potent activity against a wide range of Gram positive species including many nosocomial pathogens. More specifically, our aim was to investigate if lacticin 3147 activity could be enhanced when combined with a range of different clinical antibiotics.
Initial screening revealed that polymyxin B and polymyxin E (colistin) exhibited synergistic activity with lacticin 3147. Checkerboard assays were performed against a number of strains, including both Gram positive and Gram negative species. The resultant fractional inhibitory concentration (FIC) index values established that, while partial synergy was detected against Gram positive targets, synergy was obvious against Gram negative species, including Cronobacter and E. coli.
Combining lacticin 3147 with low levels of a polymyxin could provide a means of broadening target specificity of the lantibiotic, while also reducing polymyxin use due to the lower concentrations required as a result of synergy.
KeywordsAntimicrobial Synergy Lantibiotic Bacteriocin Lacticin 3147 Polymyxin
The challenge presented by the emerging problem of antibiotic resistance is a significant one. One approach has been to identify new bactericidal agents while another has involved a re-examination of the potential of previously identified antimicrobials. With this latter route in mind, there has been a particular focus on assessing and enhancing the benefits of applying lantibiotics in clinical settings [1, 2]. Lantibiotics are ribosomally synthesised antimicrobial peptides that are subjected to post-translational modification, resulting in the presence of unusual amino acids including intramolecular lanthionine and β-methyl lanthionine bridges. These bridges are formed through a two-step process that is initiated by the dehydration of serine and threonine residues to dehydroalanine (dha) and dehydrobutyrine (dhb), respectively. The subsequent reaction of these modified amino acids with intrapeptide cysteines results in the formation of lanthionine (Ala-S-Ala; in the case of dha) or β-methyl-lanthionine (Abu-S-Ala; in the case of dhb) bridges (for reviews see [3–5]). Lacticin 3147 is a two peptide lantibiotic which exhibits broad spectrum activity against Gram positive targets. The two lacticin 3147 peptides, Ltnα and Ltnβ, work synergistically in a 1:1 ratio [5, 6]. Ltnα first binds to the precursor of peptidoglycan production, lipid II, with Ltnβ subsequently interacting with this complex. The net effect is the inhibition of peptidoglycan synthesis and the formation of a membrane depolarising pore .
Some lantibiotics are active at single nanomolar levels against particular targets and several lantibiotics inhibit drug–resistant Gram positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) [1, 2]. Lantibiotics are highly stable, resistance is rare and activity can be enhanced through genetic alteration and, thus, they are considered to be viable alternatives to traditional antibiotics . Lacticin 3147 inhibits many Gram positive pathogens including Listeria monocytogenes, Staphylococcus aureus and Clostridium difficile as well as a variety of streptococci, enterococci and mycobacteria [8–10]. However, to date, the inhibition of Gram negative species by lacticin 3147 has not been reported. This is most often attributed to the presence of the outer membrane, which prevents access of the lantibiotic to the cytoplasmic membrane.
There are many potential benefits associated with identifying antibiotics that function synergistically with lacticin 3147. While antibiotic resistance has become a major obstacle, significant resistance to lacticin 3147 has yet to be reported and thus the use of antibiotic-lacticin 3147 combinations may prevent/overcome the emergence of resistance. Furthermore, certain antibiotic-lacticin 3147 combinations may allow for a broader range of species to be targeted. Here we assess the impact of combining lacticin 3147 with a variety of clinical antibiotics and establish that lacticin 3147 exhibits synergistic activity in combination with either polymyxin B or polymyxin E.
Sensitivity of bacteria to lacticin 3147 and antibiotics in combination
MIC data for lacticin 3147, polymyxin B and polymyxin E alone and in combination
Salmonella Typhimurium UK1
Salmonella Typhimurium LT2
Cronobacter sakazakii DPC 6440
E. coli 0157:H-
E. coli DH5α
E. coli EC101
E. faecium DO
B. cereus 8079
S .aureus 5247
Corresponding studies with three E. coli strains again revealed synergism between lacticin 3147 and the polymyxins. An FIC index value of 0.248 was obtained when lacticin 3147 and polymyxin B were combined against 0157:H- while the corresponding lacticin 3147 and polymyxin E FIC value was 0.188. When lacticin 3147 and polymyxin B were combined against E. coli DH5α and EC101, FIC indices of 0.188 and 0.5 were obtained, respectively. In addition, an FIC index of 0.188 was determined when lacticin 3147 and polymyxin E were combined for these two target strains.
A number of additional assays were carried out in order to determine if the benefits of combining lacticin 3147 and the polymyxins in broth extended to Gram positive targets. For this purpose Bacillus cereus 8079, Enterococcus faecium DO and Staphylococcus aureus 5247 were selected as representative indicator strains. It was established that, while some partial synergy between lacticin 3147 and polymyxin B was observed with respect to B. cereus 8079 and S. aureus 5247 (FIC = 0.62 and 0.75, respectively), the other combinations resulted in an additive or indifferent outcome.
MIC data for lacticin 3147, and its individual peptides Ltnα and Ltnβ, polymyxin B and polymyxin E alone and in combination
231 (37.5 μM)
(α :124.74, Β: 106.26)
28.875 / 0.0147*
14.4375 / 0.0195*
187.11 (56.25 μM)
93.555 / 0.0073
(1.5 X Ltnα)
(6.0 X Ltnα in combin.)
(6.0 X Ltnα in combin.)
495.88 (175 μM)
61.9850 / 0.0147
30.9925 / 0.0195
(4.7 X Ltnβ)
(4.7 X Ltnβ in combin.)
(4.7 X Ltnβ in combin.)
We undertook a series of investigations to determine whether lacticin 3147 acts synergistically with a range of clinically important antibiotics. Antibiotics encompassing many families and modes of action were chosen, including cephalosporins, polypeptides, glycopeptides, carbenems, and quinolones. Following this initial screen, it became clear that lacticin 3147 and the polymyxins acted synergistically.
Polymyxins are a group of polypeptide antibiotics that exclusively target Gram negative microorganisms. The five distinct members of this group, polymyxin A-E, were discovered in 1947 and are produced non-ribosomally by different Bacillus polymyxa species . Polymyxin B and polymyxin E (also referred to as colistin), have been used in clinical practice for decades in otic and ophthalmic solutions [12, 13]. Polymyxins are decapeptide antibiotics which consist of a heptapeptide ring, with polymyxin E differing from polymyxin B only by the presence of D-Leu in lieu of a D-Phe. This ring is linked to a tripeptide side-chain which carries an aliphatic chain attached via an amide bond to the amino terminus . The polymyxins carry five positive charges due to the presence of L-α-γ-diaminobutyric acids  and it has been established that the amphiphilic nature of this molecule gives it the ability to interact, bind and traverse the Gram negative outer membrane. The target molecule is lipopolysaccharide (LPS) , and specifically the lipid A component [16, 17]. The polymyxins dissociate protective divalent cations from their association with anionic LPS. This displacement permeabilises the Gram negative outer membrane to allow the polymyxins, or other cationic peptides, to form pores . It should be noted, however, that the use of polymyxins in clinical settings has been restricted to use only where drug resistant pathogens have been encountered. This is due to the toxicity, primarily nephro- and neuro-toxicity, associated with its use , although this toxicity has been suggested to be dose dependent . Nonetheless, the polymyxins are, in many cases, the only antibiotics capable of overcoming specific drug resistant pathogens such as Pseudomonas aeruginosa and Acinetobacter baumannii in cystic fibrosis patients (for reviews see [21–23]). For this reason the polymyxins cannot be ignored, but strategies that could reduce the dose needed for these antibiotics to be effective are highly desirable.
A number of studies have investigated the consequences of combining various antibiotics with polymyxins. Antimicrobial agents such as miconazole , rifampicin [25, 26] meropenem, ampicillin-sulbactam, ciprofloxacin, piperacillin-clavulanic acid, imipenem, amikacin, and gentamicin  ciprofloxacin  trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin , to name but a few, have been the focus of studies to assess if they can work synergistically with polymyxins (also see Yahav et. al., for a review of compounds synergistic with polymyxin E ). To date the only lantibiotic to have been investigated in this way is nisin, which displays synergy with polymyxin B and polymyxin E against Listeria and E. coli[31, 32]. Nisin has also been shown to function synergistically when combined with polymyxin E (and clarithromycin) against Pseudomonas aeruginosa. Combination studies have also recently revealed that lacticin 3147 and the lactoperoxidase system (LPOS) successfully inhibited growth of Cronobacter spp. in rehydrated infant formula . Lacticin 3147, like nisin, is a food grade bactericidal agent obtained from the GRAS organism Lactococcus lactis. Notably, however, it differs from nisin with respect to its target specificity and its greater potency against a number of species . Also the mechanism of action contrasts from the single nisin peptide, in that it requires the interaction of two peptides, Ltnα and Ltnβ, for optimal bactericidal activity.
Here, we report the first study to investigate whether synergy can occur between polymyxin(s) and a two-component lantibiotic. Not only do we reveal that synergy is apparent against a range of strains tested, we also investigated the individual contributions of Ltnα and Ltnβ. We established that, when combined with polymyxin B/E, the levels of lacticin 3147 required to inhibit Gram negative species are equivalent or lower than the levels of lacticin 3147 alone against many Gram positive targets. Thus, in the presence of 0.3125 μg/ml polymyxin B/E, the concentration of lacticin 3147 required to inhibit Cronobacter spp. is less than the lacticin 3147 MIC for Mycobacterium avium subsp. paratuberculosis (MAP) ATCC 19698 or Mycobacterium kansasii CIT11/06 . Similarly the MIC of lacticin 3147 (alone) against many S. aureus (which includes many of the nosocomial pathogens: methicillin-resistant S. aureus (MRSA), S. aureus with intermediate resistance to vancomycin (VISA), S. aureus with heterogenous vancomycin intermediate resistance (hVISA)) [10, 35], is greater than that required to inhibit E. coli species when in the presence of a polymyxin. It is also important to note that synergy with lacticin 3147 may provide a means of reducing the dose of polymyxins required to inhibit specific targets, thereby addressing polymyxin-associated toxicity issues. For example, 8-fold and 16-fold lower levels of the polymyxins are required to inhibit E. coli and Cronobacter when in the presence of lacticin 3147. Furthermore a recent study by Naghmouchi et al., has shown that in addition to its role in providing synergy with polymyxin E, the lantibiotic nisin appears, at certain concentrations, to eliminate its toxicity, as seen in Vero cell lines . Having established the role lacticin 3147 has in polymyxin synergy, further investigations are warranted in order to ascertain if such toxicity preventing attributes are common amongst lantibiotics.
As with previous studies , the solo activities of polymyxin B and polymyxin E against the strains tested here are very similar. With respect to the dual action of lacticin 3147 and polymyxins, it appears that the lacticin 3147-polymyxin B combination has the greater potency against Gram positive targets but that the lacticin 3147-polymyxin E combination has a greater effect against Gram negative strains. Thus, the single amino acid difference between the two polymyxin peptides appears to have an impact on its bactericidal action and target specificity when combined with lacticin 3147. It was also notable that the lacticin 3147 sensitivity of Gram positive microorganisms such as Enterococcus faecium DO, which is already highly sensitive to lacticin 3147, is not enhanced by the presence of the polymyxins. However, in the case of the strains that are relatively more lacticin 3147 resistant, the benefits of adding polymyxin B (especially with respect to Gram positive strains) and polymyxin E (especially for Gram negative strains) is most apparent. It is interesting to note that this phenomenon does not correlate with results obtained during the initial agar based disc assay screen, where the opposite pattern was observed. However, it is acknowledged that the agar-based screen is a much cruder assay, and in that instance polymyxin concentrations were fixed and only lacticin 3147 concentrations were altered. Moreover, no FIC data can be derived and so increased zone sizes may not represent the optimal combination of the antimicrobials as obtained through checkerboard assays. The mechanism by which this synergy occurs with respect to Gram negative targets is presumably based on the action of polymyxin permeabilising the outer membrane to allow lacticin 3147 to gain access to the cytoplasmic membrane and its lipid II target . However, a phenomenon concerning the synergy between polymyxin B/E and the singular peptides Ltnα and Ltnβ is also unveiled during this study. Considering the action of the singular peptides in the absence of polymyxin, a greater quantity of Ltnβ alone, than Ltnα alone, is required to inhibit E. coli (4.7 times versus 1.5 times respectively). This is logical in that Ltnα has been shown to have greater solo activity, and can bind to lipid II and prevent peptidoglycan synthesis . However in the presence of polymyxin B/E, Ltnα needs to be added at a 6 times greater concentration to bring about an inhibitory effect equal to that achieved by Ltnα:Ltnβ combined. In contrast, Ltnβ only needs to be added at a 4.7 fold greater concentration to compensate for the absence of Ltnα and thus Ltnβ seems more potent than Ltnα in the presence of either polymyxin. It is not clear if this is due to the potency of Ltnα being slightly compromised by the activity of the polymyxins or is a reflection of a particularly beneficial interaction between these antibiotics and Ltnβ. Additional studies will be required in order to investigate this further.
Regardless of the mechanism involved, this study documents a means by which lacticin 3147 can be combined with polymyxins in order to effectively inhibit some Gram negative species. There are a number of practical implications to these findings but these will require in vivo analysis. One outcome may be to ultimately facilitate the use of lower concentrations of polymyxins in situations where the levels currently employed are of concern from a toxicity perspective. Alternatively, enhancing the spectrum of lacticin 3147 to include Gram negative targets could have benefits with respect to, for example, the treatment of bovine mastitis. While lacticin 3147 has been established as being effective with respect to controlling bovine mastitis caused by Gram positive microorganisms, reducing levels of S. aureus, Streptococcus dysgalactiae or Streptococcus uberis[39, 40], mastitis can also be caused by Gram negative species and in particular by E. coli species [41, 42], against which lacticin 3147 has limited efficacy. E. coli can be considered the quintessential environmental pathogen with respect to mastitis. Infections tend to result in acute and often severe clinical mastitis and account for as many as 30% to 40% of clinical mastitis cases . Combining lacticin 3147 with low levels of a polymyxin could provide a means of broadening target specificity, for example in the treatment of mastitis, while keeping the concentrations of antimicrobial employed to a minimum.
Cultures and growth conditions
Salmonella Typhimurium UK1, Salmonella Typhimurium LT2, Escherichia coli 0157:H- , E. coli EC101, E. coli DH5α (University College Cork (UCC) culture collection) and Cronobacter sakazakii 6440 (Dairy Products Research Centre (DPC) collection) were grown in Luria-Bertani (LB) broth and agar at 37°C, while Bacillus cereus 8079 (DPC collection) and Enterococcus faecium strains DO , EC538, EC295 and EC725 (British Society for Antimicrobial Chemotherapy (BSAC)) were grown in Brain Heart Infusion (BHI) broth and agar (Oxoid Ltd., Basingstoke, Hampshire, England) at 37°C. Staphylococcus aureus strains ST528, ST523, ST530, ST291, ST534 (BSAC) and 5247 (DPC collection) were also grown at 37°C but with aeration in cation supplemented Mueller Hinton broth and Mueller Hinton agar (Oxoid Ltd., Basingstoke, Hampshire, England). Lactococcus lactis MG1363 (UCC collection) was grown at 30°C without aeration in M17 broth (Oxoid Ltd., Basingstoke, Hampshire, England) supplemented with 0.5% (wt/vol) glucose (GM17).
Cefoperazone, Cefaclor, Teicoplanin, Bacitricin, Colistin sulphate (polymyxin E), polymyxin B, oxacillin and fusidic acid antimicrobial susceptibility discs were purchased from Oxoid. Polymyxin B and colistin sulphate (polymyxin E) were obtained from Sigma-Aldrich while lacticin 3147 was purified using the following procedure: TYG media (tryptone, 2.5 g/l; yeast extract, 5.0 g/l; glucose, 10 g/l; β-glycerophosphate, 19.0 g/l; MgSO4 x 7H2O, 0.25g/l; MnSO4.4H2O, 0.05g/l) was passed through 500g XAD-16 beads (Sigma-Aldrich Company Ltd., Dorset, England) in order to remove all hydrophobic components. An overnight culture of L. lactis MG1363.pMRC01.pOM02  was then used to inoculate 1L of the modified TYG broth (1% inoculum) and incubated at 30°C overnight. The cells were subsequently harvested by centrifugation (7000g for 20 min) and resuspended in 250 ml 70% propan-2-ol, pH2 (adjusted to pH2 with addition of conc. HCl). Following stirring at 4°C for four hours the cell debris was removed by centrifugation and the supernatant was subjected to rotary evaporation (50 mbar at 40°C) to reduce the volume to ~60 ml via removal of propan-2-ol. The resultant preparation was applied to a 10 g/60 ml Strata C-18E Giga-Tube (Phenomenex, Cheshire, UK) after pre-equilibration with 60 ml methanol followed by 60 ml water. The column was subsequently washed with 120 ml of 30% ethanol and the lantibiotic was then eluted from the column via addition of 100 ml of 70% propan-2-ol, pH2. From the 100 ml preparation, 20 ml volumes were subjected to rotary evaporation in order to reduce them to ~1.7 ml through removal of propan-2-ol. Aliquots of 1800 μl were then applied to a Phenomenex (Phenomenex, Cheshire, UK) C12 reverse phase (RP)-HPLC column (Jupiter 4 μ 90Å 250 × 10.0 mm, 4 μm) previously equilibrated with 25% propan-2-ol containing 0.1% trifluoroacetic acid (TFA). The column was then developed in a gradient of 30% propan-2-ol containing 0.1% TFA to 60% propan-2-ol containing 0.1% TFA in 4 to 40 min at a flow rate of 1.2 ml/min. Fractions containing Ltnα and Ltnβ were collected after each HPLC run and stored under nitrogen gas. The Ltnα and Ltnβ containing fractions were pooled separately and subsequently subjected to rotary evaporation to remove all propan-2-ol before freeze-drying of the peptides. The Ltnα and Ltnβ peptides were weighed in μg quantities using a Mettler UMT2 micro-balance.
Antibiotic disc-based assessment of antimicrobial sensitivity and synergy
The sensitivities of S. Typhimurium LT2, C. sakazakii 6440, S. aureus, and E. faecium strains to a variety of antibiotics were determined by antibiotic disc diffusion assays as described previously . Briefly, stationary-phase cultures (16 h) were diluted to 107 CFU/ml and swabbed onto Mueller Hinton, LB or BHI agar plates. Six mm antibiotic discs (Oxoid) infused with specific antibiotics were placed on the agar plates. On the same plate lacticin 3147 (1.2, 1.9 or 2.5 μg) was added to a second antibiotic-containing disc and to a blank disc (control). Following overnight incubation (16 h) at 37°C, the resultant zones of inhibition were measured. The antibiotic discs employed included cefotaxime, novobiocin, cefoperazone, teicoplanin, ceftazidime, cefaclor, cephradine, cefaclor (30 μg), bacitracin, imipenem, fusidic acid (10 μg), penicillin G (5 μg), oxacillin (1 μg), colistin sulphate (polymyxin E) (25 μg) and polymyxin B (300U).
Minimum inhibitory concentrations
MIC determinations were carried out in triplicate in 96 well microtitre plates as previously described by Wiedemann et al., 2006. Briefly, bacterial strains were grown overnight in the appropriate conditions and medium, subcultured into fresh broth and allowed to grow to an OD600nm of ~0.5. Serial two-fold dilutions of the lacticin 3147, polymyxin B or colistin sulphate were made in the growth medium of the respective strain. Bacteria were then diluted and added to each microtitre well resulting in a final concentration of 105 cfu/ml in each 0.2 ml MIC test well. After incubation for 16 h at 37°C, the MIC was read as the lowest peptide concentration causing inhibition of visible growth.
Checkerboard assay for combining antimicrobials
In order to analyse combinations of two different antimicrobials (e.g. X and Y), the minimum inhibitory concentration of each antimicrobial has to be defined against a specific strain. Once this is known a 2-fold serial dilution of X is made horizontally in broth (50 ul) in a microtitre plate beginning at 8 x MIC for X. In a second microtitre plate, a similar dilution of Y is created and then 50 ul of this is added vertically to the original microtitre plate containing the dilution of X. Bacteria were then added in the same fashion as performed for the singular peptide minimum inhibitory assays described previously. Fractional Inhibitory Concentration (FIC) index is defined by the following equation: FIC = FICX + FICY = (X/MICX) + (Y/MICY). Where (X) is the lowest level of antimicrobial X in combination with another to achieve an inhibitory effect, while (MICx) is the MIC of that antimicrobial alone for the bacterial strain under investigation. FIC index results are interpreted as follows: FIC ≤ 0.5 is synergy, 0.5 < FIC ≤ 0.75 is partial synergy, 0.75 < FIC ≤ 1.0 is additive, FIC >1.0 is indifferent and FIC > 4 is antagonistic .
This work was supported by the Irish Government under the National Development Plan, through Science Foundation Ireland Investigator award (10/IN.1/B3027).
- Cotter PD, Ross RP, Hill C: Bacteriocins - a viable alternative to antibiotics?. Nat Rev Microbiol. 2013, 11: 95-105.PubMedView ArticleGoogle Scholar
- Piper C, Cotter PD, Ross RP, Hill C: Discovery of medically significant lantibiotics. Curr Drug Discov Technol. 2009, 6: 1-18. 10.2174/157016309787581075.PubMedView ArticleGoogle Scholar
- Chatterjee C, Paul M, Xie L, van der Donk WA: Biosynthesis and mode of action of lantibiotics. Chem Rev. 2005, 105: 633-684. 10.1021/cr030105v.PubMedView ArticleGoogle Scholar
- Bierbaum G, Sahl HG: Lantibiotics: mode of action, biosynthesis and bioengineering. Curr Pharm Biotechnol. 2009, 10: 2-18. 10.2174/138920109787048616.PubMedView ArticleGoogle Scholar
- Suda S, Cotter PD, Hill C, Ross RP: Lacticin 3147–biosynthesis, molecular analysis, immunity, bioengineering and applications. Curr Protein Pept Sci. 2012, 13: 193-204. 10.2174/138920312800785021.PubMedView ArticleGoogle Scholar
- Morgan SM, O'Connor PM, Cotter PD, Ross RP, Hill C: Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother. 2005, 49: 2606-2611. 10.1128/AAC.49.7.2606-2611.2005.PubMedPubMed CentralView ArticleGoogle Scholar
- Wiedemann I, Bottiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG: The mode of action of the lantibiotic lacticin 3147–a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol. 2006, 61: 285-296. 10.1111/j.1365-2958.2006.05223.x.PubMedView ArticleGoogle Scholar
- Carroll J, Draper LA, O'Connor PM, Coffey A, Hill C, Ross RP, Cotter PD, O'Mahony J: Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents. 2010, 36 (2): 132-136. 10.1016/j.ijantimicag.2010.03.029.PubMedView ArticleGoogle Scholar
- Rea MC, Clayton E, O'Connor PM, Shanahan F, Kiely B, Ross RP, Hill C: Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol. 2007, 56: 940-946. 10.1099/jmm.0.47085-0.PubMedView ArticleGoogle Scholar
- Iancu C, Grainger A, Field D, Cotter P, Hill C, Ross RP: Comparison of the potency of the lipid II targeting antimicrobials nisin, lacticin 3147 and vancomycin against Gram-positive bacteria. Probiotics Antimicrob Proteins. 2012, 4: 108-115. 10.1007/s12602-012-9095-x.View ArticleGoogle Scholar
- Storm DR, Rosenthal KS, Swanson PE: Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977, 46: 723-763. 10.1146/annurev.bi.46.070177.003451.PubMedView ArticleGoogle Scholar
- Ohzawa R: The use of colimycin ear drops. Jibiinkoka. 1965, 37: 585-590.PubMedGoogle Scholar
- Nakajima S: Clinical use of colimycin F otic solution. Jibiinkoka. 1965, 37: 693-697.PubMedGoogle Scholar
- Velkov T, Thompson PE, Nation RL, Li J: Structure–activity relationships of polymyxin antibiotics. J Med Chem. 2010, 53: 1898-1916. 10.1021/jm900999h.PubMedPubMed CentralView ArticleGoogle Scholar
- Vaara M: Agents that increase the permeability of the outer membrane. Microbiol Rev. 1992, 56: 395-411.PubMedPubMed CentralGoogle Scholar
- Morrison DC, Jacobs DM: Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. 1976, 13: 813-818. 10.1016/0019-2791(76)90181-6.PubMedView ArticleGoogle Scholar
- Srimal S, Surolia N, Balasubramanian S, Surolia A: Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J. 1996, 315 (Pt 2): 679-686.PubMedPubMed CentralView ArticleGoogle Scholar
- Hancock RE: The bacterial outer membrane as a drug barrier. Trends Microbiol. 1997, 5: 37-42. 10.1016/S0966-842X(97)81773-8.PubMedView ArticleGoogle Scholar
- Falagas ME, Kasiakou SK: Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006, 10: R27-10.1186/cc3995.PubMedPubMed CentralView ArticleGoogle Scholar
- Evans ME, Feola DJ, Rapp RP: Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother. 1999, 33: 960-967. 10.1345/aph.18426.PubMedView ArticleGoogle Scholar
- Falagas ME, Kasiakou SK: Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis. 2005, 40: 1333-1341. 10.1086/429323.PubMedView ArticleGoogle Scholar
- Zavascki AP, Goldani LZ, Li J, Nation RL: Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother. 2007, 60: 1206-1215. 10.1093/jac/dkm357.PubMedView ArticleGoogle Scholar
- Yuan Z, Tam VH: Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. Expert Opin Investig Drugs. 2008, 17: 661-668. 10.1517/13543722.214.171.1241.PubMedView ArticleGoogle Scholar
- Pietschmann S, Hoffmann K, Voget M, Pison U: Synergistic effects of miconazole and polymyxin B on microbial pathogens. Vet Res Commun. 2009, 33: 489-505. 10.1007/s11259-008-9194-z.PubMedPubMed CentralView ArticleGoogle Scholar
- Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H: In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother. 2003, 15: 235-238.PubMedView ArticleGoogle Scholar
- Giamarellos-Bourboulis EJ, Xirouchaki E, Giamarellou H: Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2001, 40: 117-120. 10.1016/S0732-8893(01)00258-9.PubMedView ArticleGoogle Scholar
- Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME: Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005, 49: 3136-3146. 10.1128/AAC.49.8.3136-3146.2005.PubMedPubMed CentralView ArticleGoogle Scholar
- Hoiby N, Frederiksen B, Pressler T: Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005, 4 (Suppl 2): 49-54.PubMedView ArticleGoogle Scholar
- Vidaillac C, Benichou L, Duval RE: In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2012, 56: 4856-4861. 10.1128/AAC.05996-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Yahav D, Farbman L, Leibovici L, Paul M: Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012, 18: 18-29. 10.1111/j.1469-0691.2011.03734.x.PubMedView ArticleGoogle Scholar
- Naghmouchi K, Drider D, Baah J, Teather R: Nisin A and polymyxin B as synergistic inhibitors of Gram-positive and Gram-negative bacteria. Probiotics Antimicrob Proteins. 2010, 2: 98-103. 10.1007/s12602-009-9033-8.View ArticleGoogle Scholar
- Naghmouchi K, Belguesmia Y, Baah J, Teather R, Drider D: Antibacterial activity of class I and IIa bacteriocins combined with polymyxin E against resistant variants of Listeria monocytogenes and Escherichia coli. Res Microbiol. 2011, 162: 99-107. 10.1016/j.resmic.2010.09.014.PubMedView ArticleGoogle Scholar
- Giacometti A, Cirioni O, Barchiesi F, Fortuna M, Scalise G: In vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother. 1999, 44: 641-645. 10.1093/jac/44.5.641.PubMedView ArticleGoogle Scholar
- Oshima S, Rea MC, Lothe S, Morgan S, Begley M, O'Connor PM, Fitzsimmons A, Kamikado H, Walton R, Ross RP, Hill C: Efficacy of organic acids, bacteriocins, and the lactoperoxidase system in inhibiting the growth of Cronobacter spp. in rehydrated infant formula. J Food Prot. 2012, 75: 1734-1742. 10.4315/0362-028X.JFP-12-066.PubMedView ArticleGoogle Scholar
- Piper C, Draper LA, Cotter PD, Ross RP, Hill C: A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother. 2009, 64: 546-551. 10.1093/jac/dkp221.PubMedView ArticleGoogle Scholar
- Naghmouchi K, Baah J, Hober D, Jouy E, Rubrecht C, Sane F, Drider D: Synergistic effect between colistin and bacteriocins in controlling Gram-negative pathogens and their potential to reduce antibiotic toxicity in mammalian epithelial cells. Antimicrob Agents Chemother. 2013, 57: 2719-2725. 10.1128/AAC.02328-12.PubMedPubMed CentralView ArticleGoogle Scholar
- Gales AC, Reis AO, Jones RN: Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001, 39: 183-190. 10.1128/JCM.39.1.183-190.2001.PubMedPubMed CentralView ArticleGoogle Scholar
- Hermsen ED, Sullivan CJ, Rotschafer JC: Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am. 2003, 17: 545-562. 10.1016/S0891-5520(03)00058-8.PubMedView ArticleGoogle Scholar
- Klostermann K, Crispie F, Flynn J, Meaney WJ, Ross RP, Hill C: Efficacy of a teat dip containing the bacteriocin lacticin 3147 to eliminate Gram-positive pathogens associated with bovine mastitis. J Dairy Res. 2010, 77: 231-238. 10.1017/S0022029909990239.PubMedView ArticleGoogle Scholar
- Ryan MP, Meaney WJ, Ross RP, Hill C: Evaluation of lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ Microbiol. 1998, 64: 2287-2290.PubMedPubMed CentralGoogle Scholar
- Shpigel NY, Elazar S, Rosenshine I: Mammary pathogenic Escherichia coli. Curr Opin Microbiol. 2008, 11: 60-65. 10.1016/j.mib.2008.01.004.PubMedView ArticleGoogle Scholar
- Schukken Y, Chuff M, Moroni P, Gurjar A, Santisteban C, Welcome F, Zadoks R: The "other" Gram-negative bacteria in mastitis: Klebsiella, Serratia, and more. Vet Clin North Am Food Anim Pract. 2012, 28: 239-256. 10.1016/j.cvfa.2012.04.001.PubMedView ArticleGoogle Scholar
- Hogan JS, Smith KL: A practical look at environmental mastitis. Comp Cont Educ Pract. 1987, 9: F341-F346.Google Scholar
- Arduino RC, Murray BE, Rakita RM: Roles of Antibodies and Complement in Phagocytic Killing of Enterococci. Infection and Immunity. 1994, 62: 987-993.PubMedPubMed CentralGoogle Scholar
- Cotter PD, Draper LA, Lawton EM, McAuliffe O, Hill C, Ross RP: Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Appl Environ Microbiol. 2006, 72: 4492-4496. 10.1128/AEM.02543-05.PubMedPubMed CentralView ArticleGoogle Scholar
- Collins B, Curtis N, Cotter PD, Hill C, Ross RP: The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. Antimicrob Agents Chemother. 2010, 54: 4416-4423. 10.1128/AAC.00503-10.PubMedPubMed CentralView ArticleGoogle Scholar
- Neu HC: Mecillinam––an amidino penicillin which acts synergistically with other beta-lactam compounds. J Antimicrob Chemother. 1977, 3 (Suppl B): 43-52. 10.1093/jac/3.suppl_B.43.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.